What Is Non-Invasive Cancer and How Is It Treated?

Non-invasive cancer is made of cells that look like cancer but have stayed in the place where they began, without growing into the tissue around them. Because they have not escaped, they cannot spread to other parts of the body, which is why the outlook is usually excellent.¹ They still matter, though, because some can become invasive over time if left alone, and treatment aims to stop that step from happening.² For many people, treatment is a local job, removing or destroying the cells where they sit, and doctors increasingly debate how much treatment low-risk cases really need.

What Non-Invasive Means Inside Your Body

Most of these cancers start in the lining layer that covers your skin and lines the milk ducts, the bladder and the cervix. Beneath that lining sits the basement membrane, a thin sheet of support material that acts like a floor.³ Carcinoma in situ (CIS), Latin for “in place,” means the abnormal cells are still entirely above that floor and it is intact.⁴ Blood vessels and lymph channels lie below the floor, so cells that haven’t crossed it have no route to travel.⁵ Invasive cancer has broken through, and that is what gives it the ability to spread.⁶

In breast cancer, the boundary layer is gradually lost as in situ disease turns invasive.⁷ Once cells touch the tougher tissue below, that contact itself can spur them to push further.⁸

Some reports mention “microinvasion,” meaning a tiny cluster of cells, often within 1 to 2 mm, has just crossed the boundary. That is no longer purely non-invasive and may change the treatment plan, so ask your doctor whether your report mentions it and what it changes.

A mammogram or other scan can show an abnormal area, but it can’t show whether cells have crossed a boundary that thin. The label comes from a pathologist examining tissue from a biopsy or surgery. A biopsy samples only part of the area, so the fully removed tissue may reveal a small invasive spot the sample missed.

Is Non-Invasive Cancer Dangerous

Stage 0 is the staging label for cancer that has not invaded, and doctors classify it as the earliest stage. Some stage 0 cancers can become dangerous over time, especially if left untreated.⁹ The risk varies by type. In the throat and mouth, severe precancerous change can be more likely to progress than classic in situ cancer.¹⁰

Because the risk is low but not zero, some experts argue that “precancer” or “non-invasive cancer” better fits these cells.¹¹ Clinicians have warned that the fear the word “cancer” triggers can push people toward more treatment than they need.¹²

Part of the debate comes from overdiagnosis, which means finding a growth that would never have caused harm in your lifetime. Screening finds many in situ cancers that cause no symptoms, and doctors cannot yet reliably tell which ones would progress. That is why most are still treated.

To understand your own risk, ask what grade the cells are, since higher grade usually means more likely to progress. Ask whether the report says the boundary layer is intact everywhere. And ask what happens to people with your exact findings who choose less treatment.

The Common Types and Where They Are Found

DCIS (ductal carcinoma in situ) is made of cancer-like cells inside the milk ducts that have not left them. Most DCIS contains tiny calcium specks that show as white dots on a mammogram.¹³ Screening-found DCIS usually shows up as these specks, while DCIS found because of a symptom more often shows as a lump.¹⁴ To confirm there is no invasion, pathologists check for an intact layer of support cells around the duct, which invasive cancer usually lacks.¹⁵

In the bladder, tumours on the lining surface are stage Ta, flat in situ lesions are Tis, and those growing into the next layer are T1.¹⁶ About 3 in 4 non-invasive papillary bladder tumours found are Ta, which carry a fairly low risk of turning invasive.¹⁷ Flat bladder CIS is always considered high grade.¹⁸ These tumours often come back, with between about 3 and 8 in 10 recurring.¹⁹

Cervical CIN3 and adenocarcinoma in situ are almost always caused by HPV, found in about 98 to 99% of cases.²⁰ Lasting HPV16 infection carries the highest risk, with about a 55% chance of CIN3 or worse over 8 years.²¹ Because HPV causes nearly all CIN3, vaccines against HPV16 and 18 prevent most cases, and regular cervical screening catches CIN3 before it becomes invasive.

On skin, in situ cancers include melanoma in situ, lentigo maligna on sun-damaged skin, and squamous cell carcinoma in situ, also called Bowen’s disease.

Surgery for DCIS

A lumpectomy removes the DCIS with a rim of normal tissue. The margin is the distance from the DCIS to the edge of what was removed. The usual goal for DCIS lumpectomy followed by radiation is a 2 mm clear margin.²² Edges narrower than 2 mm raised the 10-year risk of DCIS or cancer returning in that breast only from about 3.8% to 5.3% in women who also had radiation and hormone pills.²³ Clear edges wider than 2 mm don’t improve control, and a routine second operation for a negative but close margin isn’t supported.²⁴

On the day, most lumpectomies are done under general anaesthetic, and many people go home the same day. If the DCIS is only visible as calcium specks, a radiologist often places a thin wire or small marker beforehand so the surgeon knows exactly where to cut. The removed tissue goes to a pathologist, who inks its outer surface and checks how close the DCIS comes to each edge. Results usually take a week or two, and that is when you learn whether the goal was met.

If you are told you need a re-excision, ask whether the edge was positive, meaning cells touch it, or just close. A close but clear edge may not need another operation if you will have radiation. Ask how much extra protection a second surgery would give you.

After mastectomy for DCIS, the risk of it coming back is low and doesn’t seem to depend on edges or radiation.²⁵ Choosing between the two is often about preference, the size of the area and future treatment, not survival. Lumpectomy keeps most of the breast but usually needs weeks of radiation. Mastectomy usually avoids radiation but is a bigger operation with a longer recovery, and breast reconstruction is an option afterward.

Radiation and Hormone Pills After DCIS Surgery

Adding radiation after lumpectomy cut the chance of DCIS or cancer returning in the breast by about half, including invasive returns.²⁶ In absolute terms, though, radiation lowered returns by about 2.8 percentage points and breast cancer deaths by about 0.3 points.²⁷

“Halves the risk” can mean going from a small number to an even smaller one. Ask your doctor for your own numbers with and without each treatment. Low-risk DCIS gains less from extra treatment than high-grade DCIS.

Radiation treatment usually starts a few weeks after the surgical wound has healed, following a planning scan that maps the breast. Small ink dots or tattoos are often placed on the skin so the machine lines up the same way each time. Sessions are short daily visits over a few weeks, with only a few minutes of painless beam time. Skin redness and tiredness are common side effects. Some centres offer shorter courses over fewer weeks, so ask whether that is an option.

Tamoxifen blocks oestrogen and is offered when DCIS is hormone receptor positive. A low dose of 5 mg a day for 3 years halved recurrence in DCIS, with benefit lasting years after stopping and no long-term harms.²⁸ After mastectomy for hormone-positive DCIS, hormone therapy also lowered the risk of cancer in the other breast.²⁹ Tamoxifen can cause hot flushes and, rarely, blood clots, so report leg swelling or chest pain.

Treating Non-Invasive Bladder Cancer

These tumours are removed with a scope passed through the urethra, sometimes followed by medicines put directly into the bladder.³⁰ The operation is called a transurethral resection. No cut is made in the skin, and under anaesthetic the surgeon shaves the tumour off the bladder wall in pieces. You may have a catheter for a day or so, and some blood in the urine for a short while is common. A pathologist examines the pieces, including whether muscle is present in the sample, to confirm the stage.

BCG, a weakened bacterium related to the TB vaccine, is the standard for those at high risk of progression.³¹ It rallies the immune system in the bladder wall and can also directly damage cancer cells.³² It lowers recurrence and progression more than bladder chemotherapy, though with more side effects.³³ Maintenance doses are needed for the best results.³⁴

In a session, a thin tube puts the liquid into the bladder and you hold it in for about two hours before urinating. Burning on urination, frequent urination and flu-like feelings are common for a day or two. Regular cystoscopy check-ups follow because these tumours often return.

Treating Cervical and Skin In Situ Disease

Lower-grade changes often clear up as the body fights off the HPV infection, so they are usually just monitored. CIN3 is the most severe grade of cervical change, and it is far less likely to clear by itself. Removing CIN3 greatly lowers the chance of it becoming invasive cervical cancer. It is usually done with a short outpatient procedure that cuts away the affected area of the cervix, often in a clinic under local anaesthetic. Expect some bleeding or discharge for a few weeks, and ask about any effect on future pregnancies. The removed tissue is examined to check that the edges are clear and that no invasive cancer was hiding. Follow-up HPV and smear tests check that it hasn’t come back.

On the skin, surgery is the usual treatment for melanoma in situ. Creams such as imiquimod, which boosts the immune response, and 5-fluorouracil, which kills fast-growing cells, can be used, alone or together.³⁵ The combination cleared Bowen’s disease in a small group of transplant patients.³⁶ Imiquimod cleared lentigo maligna in about 3 in 4 cases, but not in the rest, so close follow-up is needed.³⁷

Cream treatment runs for weeks. Redness, crusting and soreness are common and are often a sign the cream is working. A biopsy afterward may confirm the skin is clear.

Can Low-Risk DCIS Just Be Watched

Active monitoring means regular mammograms and check-ups instead of surgery. Over 2 years, invasive cancer appeared in 4.2% of women monitored versus 5.9% given standard treatment, so monitoring was not worse in that time.³⁸

Trials limit this to women about 45 or older with low-grade DCIS found only by screening calcium specks and no symptoms.³⁹ Long-term results are still awaited.

The usual plan is a mammogram once a year, with check-ups with the breast team in between; some schedules call for them every 6 to 12 months. If a mammogram shows the area has changed, a new biopsy is typically done to see whether anything has progressed. Treatment is offered if there are signs of invasive cancer or other concerning changes. Ask whether your DCIS is low grade and hormone positive, exactly what would trigger a switch to surgery, and who will review your scans. Some people find waiting stressful and prefer surgery, and you can switch to treatment at any time.

How Doctors Predict Your Risk of Recurrence

Grade describes how abnormal the cells look under the microscope, and higher grade generally means a higher chance of return. Hormone receptor status shows whether the DCIS is fuelled by oestrogen, which decides whether hormone pills could help. Both come from the biopsy report you already have.

Genomic tests add to this picture. They examine genes in the tumour to predict how likely it is to return, and results can help decide whether radiation is needed or how long to take hormone pills.⁴⁰ In bladder cancer, certain gene changes are linked to quicker recurrence.⁴¹

Ask whether a genomic test applies to your type. Results are a risk estimate, not a guarantee, and insurance coverage varies, so check before testing.

1
MyPathologyReport. What Is Non-Invasive Cancer and How Is It Treated? ↩︎
2
The Conversation. Stage 0 cancer is often overlooked – but it could be your earliest warning sign ↩︎
3
SimpleMed+. Carcinoma in situ versus invasive carcinoma ↩︎
4
MyPathologyReport. What Is Non-Invasive Cancer and How Is It Treated? ↩︎
5
MyPathologyReport. What Is Non-Invasive Cancer and How Is It Treated? ↩︎
6
PubMed Central. Force-Dependent Breaching of the Basement Membrane ↩︎
7
PubMed Central. Illuminating breast cancer invasion: diverse roles for cell–cell interactions ↩︎
8
PubMed Central. Illuminating breast cancer invasion: diverse roles for cell–cell interactions ↩︎
9
The Conversation. Stage 0 cancer is often overlooked – but it could be your earliest warning sign ↩︎
10
PubMed. Dysplasia, in situ carcinoma, and progression to invasive squamous cell carcinoma of the upper aerodigestive tract ↩︎
11
The Conversation. Stage 0 cancer is often overlooked – but it could be your earliest warning sign ↩︎
12
Cancer World. What Is Non-Invasive Cancer and How Is It Treated? ↩︎
13
PubMed. Is Ductal Carcinoma In Situ a Precursor or Low-Risk Variant of Invasive Breast Cancer? A Population Perspective ↩︎
14
PubMed. Screening-detected and symptomatic ductal carcinoma in situ: differences in the sonographic and pathologic features ↩︎
15
PubMed. Breast myoepithelial markers: Problems and pitfalls for the practicing pathologist ↩︎
16
European Association of Urology. Pathological Staging and Classification Systems – EAU Guidelines on Non-muscle-invasive Bladder Cancer ↩︎
17
PubMed Central. Educational Case: Bladder Urothelial Cell Carcinoma TNM Stage, Prognosis and Management ↩︎
18
PubMed Central. Educational Case: Bladder Urothelial Cell Carcinoma TNM Stage, Prognosis and Management ↩︎
19
PubMed Central. Educational Case: Bladder Urothelial Cell Carcinoma TNM Stage, Prognosis and Management ↩︎
20
PubMed Central. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015 ↩︎
21
PubMed. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types ↩︎
22
PubMed Central. Margins in Breast Cancer: How Much Is Enough? ↩︎
23
The ASCO Post. Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision ↩︎
24
PubMed Central. Margins in Breast Cancer: How Much Is Enough? ↩︎
25
PubMed. Mastectomy margins for ductal carcinoma-in-situ (DCIS): 18 Years of follow-up ↩︎
26
PubMed Central. The Impact of Adding Radiation Treatment After Breast Conservation Surgery for Ductal Carcinoma In Situ of the Breast ↩︎
27
PubMed Central. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy ↩︎
28
PubMed. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study ↩︎
29
PubMed Central. Effect of adjuvant endocrine therapy on recurrence and contralateral breast cancer in HR-positive DCIS after mastectomy ↩︎
30
European Association of Urology. Pathological Staging and Classification Systems – EAU Guidelines on Non-muscle-invasive Bladder Cancer ↩︎
31
PubMed. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer ↩︎
32
Frontiers in Bioscience-Landmark. Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer ↩︎
33
PubMed. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer ↩︎
34
PubMed. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer ↩︎
35
PubMed Central. Treating Melanoma in Situ During a Pandemic with Telemedicine and a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin ↩︎
36
PubMed. Squamous cell carcinoma in situ (Bowen’s disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy ↩︎
37
PubMed Central. Lentigo Maligna Treatment—An Update ↩︎
38
PubMed Central. Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial ↩︎
39
PubMed. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study ↩︎
40
Breastcancer.org. Genomic Tests for Breast Cancer ↩︎
41
PubMed Central. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23‐gene panel with utility for non‐invasive diagnosis and risk stratification ↩︎